Virginia Devonshire

Disability progression in multiple sclerosis is slower than previously reported

Helen Tremlett, Donald W. Paty, Virginia Devonshire · Neurology · 2006 · 342 citations

Medicine, Neurology, Disability Management +13

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Longitudinal follow-up of “benign” multiple sclerosis at 20 years

Ana‐Luiza Sayao, Virginia Devonshire, Helen Tremlett · Neurology · 2007 · 146 citations

Medicine, Neurology, Disease Surveillance +15

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +9

The natural history of primary progressive MS in British Columbia, Canada

Helen Tremlett, Donald W. Paty, Virginia Devonshire · Neurology · 2005 · 102 citations

Medicine, Neurology, Disease Surveillance +11